Clinical Trial

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-02.
Status change: Not Yet Recruiting → Recruiting 2025-01-20
Trial Details
NCT Number NCT06071013
Lead Sponsor China Medical University Hospital
Collaborators: China Medical University, Taiwan
Conditions Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
Enrollment 20 participants
Start Date 2024-02-23
Primary Completion 2026-08-27 (estimated)
Study Completion 2026-08-27 (estimated)
Updated on ClinicalTrials.gov 2025-01-23